Lexeo CEO receives option for 145,500 shares
The option terms set 25% to vest and become exercisable September 24, 2027, with 1/48th vesting monthly thereafter subject to continuous service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc.’s Chief Executive Officer and director, Richard Nolan Townsend, acquired 2,306 common shares on September 14, 2026, at $2.6440 per share through the 2023 Employee Stock Purchase Plan. His reported common-share holdings after that transaction were 376,778 shares, including 242,911 restricted stock units. On September 24, 2026, he received an option covering 145,500 common shares, with a $3.3900 exercise price and a September 23, 2036 expiration.
Insider Trade Summary
Grant/Award: 147,806 shares
Grant/Award
2 txns
Insider
Townsend Richard Nolan
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F3 | 145,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2 | 2,306 | $2.644 | $6K |
Holdings After Transaction:
Stock Option (right to buy) — 145,500 contracts (Direct);
Common Stock — 376,778 shares (Direct)
Footnotes (3)
- F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
- F2. Includes 242,911 Restricted Stock Units.
- F3. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Key Figures
Common shares acquired: 2,306 shares
Acquisition price: $2.6440 per share
Reported common-share holdings: 376,778 shares
+5 more
8 metrics
Common shares acquired
2,306 shares
Acquired on September 14, 2026, through the 2023 Employee Stock Purchase Plan
Acquisition price
$2.6440 per share
Price reported for the September 14, 2026 common-share acquisition
Reported common-share holdings
376,778 shares
After the September 14, 2026 transaction; includes 242,911 Restricted Stock Units
Restricted Stock Units
242,911 units
Included in reported common-share holdings after the September 14, 2026 transaction
Common shares underlying option
145,500 shares
Option granted September 24, 2026
Option exercise price
$3.3900 per share
Option granted September 24, 2026
Initial option vesting
25%
Vests and becomes exercisable September 24, 2027
Monthly option vesting
1/48th of underlying shares
Vests in monthly installments thereafter, subject to continuous service
Key Terms
Employee Stock Purchase Plan, Restricted Stock Units, Rule 16b-3(c), Rule 16b-3(d)
4 terms
Employee Stock Purchase Plan financial
"pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Restricted Stock Units financial
"Includes 242,911 Restricted Stock Units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 16b-3(c) regulatory
"exempt under both Rule 16b-3(c) and Rule 16b-3(d)"
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
Rule 16b-3(d) regulatory
"exempt under both Rule 16b-3(c) and Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did LXEO CEO Richard Nolan Townsend acquire?
Richard Nolan Townsend acquired 2,306 common shares on September 14, 2026, at $2.6440 per share through the 2023 Employee Stock Purchase Plan, and received an option for 145,500 common shares on September 24, 2026.
How do Richard Nolan Townsend’s LXEO options vest?
The option covering 145,500 common shares vests 25% and becomes exercisable on September 24, 2027; 1/48th of the underlying shares vests in monthly installments thereafter, subject to his continuous service. The option expires September 23, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
